RATIONALE: The pharmacodynamic (PD) effects of orally administered KVD900 were evaluated using ex vivo whole plasma assays for plasma kallikrein catalytic activity and high molecular weight kininogen (HK) cleavage. METHODS: KVD900, a potent and selective small molecule plasma kallikrein inhibitor, was administered orally to 8 single ascending dose cohorts of healthy adult males (n56 active, 2 placebo per cohort). Samples for pharmacokinetic and PD assessment were taken at repeated intervals over 48hrs. PD measurements were determined in dextran sulfate (DXS)-stimulated whole plasma using a fluorogenic enzyme assay and capillarybased HK cleavage immunoassay. RESULTS: Orally administered KVD900 achieved rapid and dosedependent plasma exposure over the range of doses tested from 5mg to 600mg. The mean plasma exposure following the 600mg dose of KVD900 was 3162 +/-1031 ng/ml at 30mins and 3680 +/-846 ng/ml at 1hr. Enzyme assays demonstrated that this dose provided >90% inhibition of plasma kallikrein catalytic activity between 30mins and 6hrs post-dose and >50% inhibition for 10hrs. The 600mg dose of KVD900 protected HK from DXS-stimulated cleavage for at least 10hrs post-dose. Whilst all doses from 80mg and above were able to completely inhibit plasma kallikrein catalytic activity and consequently provide effective protection of HK cleavage, the duration of these PD effects was dose proportional. CONCLUSIONS: Orally administered KVD900 achieves rapid plasma exposure sufficient for highly effective plasma kallikrein inhibition and protection of HK cleavage. A single 600mg dose provided these effects for at least 10hrs. These properties of KVD900 are well suited as a rapidlyacting oral treatment of HAE attacks. 
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